Skip to main content
Fig. 2 | Orphanet Journal of Rare Diseases

Fig. 2

From: Antibodies against recombinant human alpha-glucosidase do not seem to affect clinical outcome in childhood onset Pompe disease

Fig. 2

Clinical parameters, anti-recombinant human acid α-glucosidase (anti-rhGAA) antibody titers, neutralizing effects and infusion associated reactions (IARs) for five patients with a high or very high peak antibody titer. Each graph represents an individual patient. For each patient, anti-rhGAA antibody titers are shown on the left Y-axis, the effect of antibody titers on intracellular rhGAA activity (%) is shown on the right Y-axis. The occurrence of IARs is displayed (exclamation marks). Clinical outcome parameters, the Medical Research Council (MRC) sum score (expressed as a percentage of maximal muscle strength), Forced Vital Capacity (FVC) in upright position (expressed as a percentage of predicted normal values) and Quick Motor Function Test (QMFT) sum score (expressed as a percentage of the maximal score), are shown on the right Y-axis

Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172